Diana McKenzie bought $45k of AGL
director at agilon health, inc.. 20,000 shares at an average of $2.25, traded Nov 25, 2024, filed Dec 11, 2024.
Score components
- +15RoleDirector
- +6Trade size$45k at market
- +10Relative to holdingsHoldings up 52%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-050832, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | POpen-market purchase Common Stock | +12,500 | $2.28 | $28k | 51,319 | Dec 11, 2024 |
| Dec 9, 2024 | POpen-market purchase Common Stock | +7,500 | $2.20 | $16k | 58,819 | Dec 11, 2024 |
Related signals
Other insiders at agilon health, inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 47Moderate | buy 3 | AGL agilon health, inc. | Silvana Battaglia director | $50k | 25,062 | |
| 47Moderate | buy 3 | AGL agilon health, inc. | Karen McLoughlin director | $55k | 25,000 | |
| 46Moderate | buy 4 | AGL agilon health, inc. | John William Wulf director | $98k | 45,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.